Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 6, 2008, Pages 761-784

  Pleguezuelo, Maria ^a   Germani, Giacomo ^a   Marelli, Laura ^a   Xiruochakis, Elias ^a   Misseri, Maria ^a   Pinelopi, Manousou ^a   Arvaniti, Vasiliki ^a   Burroughs, Andrew K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Diagnosis; Hepatocellular carcinoma; Imaging; Interventional ablation; Liver biopsy; Liver cancer; Locoregional therapy; Molecular marker

Indexed keywords

ACETIC ACID; ALCOHOL; ALPHA FETOPROTEIN; ALPHA INTERFERON; CISPLATIN; DECARBOXYPROTHROMBIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GELFOAM; GLYCOPROTEIN; GLYPICAN 3; IODINATED POPPYSEED OIL; IODINE 131; PROTEIN GP73; RADIOISOTOPE; RHENIUM 188; SORAFENIB; TAMOXIFEN; UNCLASSIFIED DRUG; YTTRIUM 90;

ACETIC ACID INJECTION; ANTIANGIOGENIC THERAPY; ASPIRATION BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHEMOEMBOLIZATION; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CRYOABLATION; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; DISEASE MARKER; DRUG MEGADOSE; ECHOGRAPHY; EXTRACORPOREAL ENERGY THERAPY; HUMAN; INTERMETHOD COMPARISON; LASER SURGERY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER SURGERY; MICROWAVE ABLATION THERAPY; MICROWAVE THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PERCUTANEOUS ETHANOL INJECTION; PORTAL VEIN THROMBOSIS; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TRANSARTERIAL RADIOEMBOLIZATION; TRANSARTERIAL RADIONUCLIDE THERAPY; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE; TUMOR VOLUME; CATHETER ABLATION; EVIDENCE BASED MEDICINE; LIVER TUMOR; SPIRAL COMPUTER ASSISTED TOMOGRAPHY;

CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; EVIDENCE-BASED MEDICINE; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; TOMOGRAPHY, SPIRAL COMPUTED;

EID: 61549109265     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.6.761     Document Type: Review

References (202)

1. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127(5 Suppl. 1), S5-S16 (2004).
2. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 42(5), 1208-1236 (2005).
3. Maruyama H, Yoshikawa M, Yokosuka O. Current role of ultrasound for the management of hepatocellular carcinoma. World J. Gastroenterol. 14(11), 1710-1719 (2008).
4. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J. Hepatol. 48(Suppl. 1), S20-S37 (2008).
5. Sodhi KS, Sidhu R, Gulati M, Saxena A, Suri S, Chawla Y. Role of tissue harmonic imaging in focal hepatic lesions: comparison with conventional sonography. J. Gastroenterol. Hepatol. 20(10), 1488-1493 (2005).
6. Konopke R, Bunk A, Kersting S. The role of contrast-enhanced ultrasound for focal liver lesion detection: an overview. Ultrasound Med. Biol. 33(10), 1515-1526 (2007).
7. Lencioni R, Piscaglia F, Bolondi L. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. J. Hepatol. 48(5), 848-857 (2008).
8. Lu MD, Yu XL, Li AH et al. Comparison of contrast enhanced ultrasound and contrast enhanced CT or MRI in monitoring percutaneous thermal ablation procedure in patients with hepatocellular carcinoma: a multicenter study in China. Ultrasound Med. Biol. 33(11), 1736-1749 (2007).
9. Baron RL, Brancatelli G. Computed tomographic imaging of hepatocellular carcinoma. Gastroenterology 127(5 Suppl. 1), S133-S143 (2004).
10. Rode A, Bancel B, Douek P G et al. Small nodule detection in cirrhotic livers: evaluation with US, spiral CT and MRI and correlation with pathologic examination of explanted liver. J. Comput. Assist. Tomogr. 25(3), 327-336 (2001).
11. de Ledinghen V, Laharie D, Lecesne R et al. Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. Eur J. Gastroenterol. Hepatol. 14(2), 159-165 (2002).
12. Libbrecht L, Bielen D, Verslype C et al. Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl. 8(9), 749-761 (2002).
13. Zacherl J, Pokieser P, Wrba F et al. Accuracy of multiphasic helical computed tomography and intraoperative sonography in patients undergoing orthotopic liver transplantation for hepatoma: what is the truth? Ann. Surg. 235(4), 528-532 (2002).
14. Teefey SA, Hildeboldt CC, Dehdashti F et al. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US and PET. Radiology 226(2), 533-542 (2003).
15. Valls C, Cos M, Figueras J et al. Pretransplantation diagnosis and staging of hepatocellular carcinoma in patients with cirrhosis: value of dual-phase helical CT. AJR Am. J. Roentgenol. 182(4), 1011-1017 (2004).
16. Kim YK, Kwak HS, Kim CS, Chung GH, Han YM, Lee JM. Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIO-enhanced MR imaging and 16-detector row CT. Radiology 238(2), 531-541 (2006).
17. Ronzoni A, Artioli D, Scardina R et al. Role of MDCT in the diagnosis of hepatocellular carcinoma in patients with cirrhosis undergoing orthotopic liver transplantation. AJR Am. J. Roentgenol. 189(4), 792-798 (2007).
18. Dai Y, Chen MH, Fan ZH, Yan K, Yin SS, Zhang XP. Diagnosis of small hepatic nodules detected by surveillance ultrasound in patients with cirrhosis: comparison between contrast-enhanced ultrasound and contrast-enhanced helical computed tomography. Hepatol. Res. 38(3), 281-290 (2008).
19. Bhattacharjya S, Bhattacharjya T, Quaglia A et al. Liver transplantation in cirrhotic patients with small hepatocellular carcinoma: an analysis of pre-operative imaging, explant histology and prognostic histologic indicators. Dig. Surg. 21(2), 152-159 (2004).
20. Choi SH, Lee JM, Yu NC et al. Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI. AJR Am. J. Roentgenol. 191(2), 529-536 (2008).
21. Brancatelli G, Baron RL, Peterson MS, Marsh W. Helical CT screening for hepatocellular carcinoma in patients with cirrhosis: frequency and causes of false-positive interpretation. AJR Am. J. Roentgenol. 180(4), 1007-1014 (2003).
22. Guevara M, Fernandez-Esparrach G, Alessandria C et al. Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology 40(3), 646-651 (2004).
23. Gonzales DA, Norsworthy KJ, Kern SJ et al. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med. 5, 32 (2007).
24. Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 247(2), 311-330 (2008).
25. Ward J, Guthrie JA, Scott DJ et al. Hepatocellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis. Radiology 216(1), 154-162 (2000).
26. Krinsky GA, Lee VS, Theise ND et al. Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation. Radiology 219(2), 445-454 (2001).
27. Krinsky GA, Lee VS, Theise ND et al. Transplantation for hepatocellular carcinoma and cirrhosis: sensitivity of magnetic resonance imaging. Liver Transpl. 8(12), 1156-1164 (2002).
28. Bhartia B, Ward J, Guthrie JA, Robinson PJ. Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. AJR Am. J. Roentgenol. 180(3), 577-584 (2003).
29. Burrel M, Llovet JM, Ayuso C et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 38(4), 1034-1042 (2003).
30. Kim YK, Kim CS, Kwak HS, Lee JM. Three-dimensional dynamic liver MR imaging using sensitivity encoding for detection of hepatocellular carcinomas: comparison with superparamagnetic iron oxide-enhanced MR imaging. J. Magn. Reson. Imaging 20(5), 826-837 (2004).
31. Hecht EM, Holland AE, Israel GM et al. Hepatocellular carcinoma in the cirrhotic liver: gadolinium-enhanced 3D T1-weighted MR imaging as a stand-alone sequence for diagnosis. Radiology 239(2), 438-447 (2006).
32. Lauenstein TC, Salman K, Morreira R et al. Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience. AJR Am. J. Roentgenol. 189(3), 663-670 (2007).
33. Forner A, Vilana R, Ayuso C et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47(1), 97-104 (2008).
34. Fung KT, Li FT, Raimondo ML et al. Systematic review of radiological imaging for hepatocellular carcinoma in cirrhotic patients. Br. J. Radiol. 77(920), 633-640 (2004).
35. Caturelli E, Biasini E, Bartolucci F et al. Diagnosis of hepatocellular carcinoma complicating liver cirrhosis: utility of repeat ultrasound-guided biopsy after unsuccessful first sampling. Cardiovasc. Intervene Radiol. 25(4), 295-299 (2002).
36. Saar B, Kellner-Weldon F. Radiological diagnosis of hepatocellular carcinoma. Liver Int. 28(2), 189-199 (2008).
37. Lencioni R, Cioni D, Crocetti L et al. Ultrasound imaging of focal liver lesions with a second-generation contrast agent. Acad. Radiol. 9(Suppl. 2), S371-S374 (2002).
38. Giorgio A, Ferraioli G, Tarantino L et al. Contrast-enhanced sonographic appearance of hepatocellular carcinoma in patients with cirrhosis: comparison with contrast-enhanced helical CT appearance. AJR Am. J. Roentgenol. 183(5), 1319-1326 (2004).
39. Bolondi L, Gaiani S, Celli N et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 42(1), 27-34 (2005).
40. Wang JH, Lu SN, Hung CH et al. Small hepatic nodules (< or =2 cm) in cirrhosis patients: characterization with contrast-enhanced ultrasonography. Liver Int. 26(8), 928-934 (2006).
41. Gaiani S, Celli N, Piscaglia F et al. Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. J. Hepatol. 41(3), 421-426 (2004).
42. Jeong YY, Yim NY, Kang HK. Hepatocellular carcinoma in the cirrhotic liver with helical CT and MRI: imaging spectrum and pitfalls of cirrhosis-related nodules. AJR Am. J. Roentgenol. 185(4), 1024-1032 (2005).
43. Zhao H, Yao JL, Wang Y, Zhou KR. Detection of small hepatocellular carcinoma: comparison of dynamic enhancement magnetic resonance imaging and multiphase multirow-detector helical CT scanning. World J. Gastroenterol. 13(8), 1252-1256 (2007).
44. Durand F, Belghiti J, Paradis V. Liver transplantation for hepatocellular carcinoma: role of biopsy. Liver Transpl. 13(11 Suppl. 2), S17-S23 (2007).
45. Durand F, Regimbeau JM, Belghiti J et al. Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J. Hepatol. 35(2), 254-258 (2001).
46. Stigliano R, Burroughs AK. Should we biopsy each liver mass suspicious for HCC before liver transplantation? No, please don't. J. Hepatol. 43(4), 563-568 (2005).
47. Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs AK. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat. Rev. 33(5), 437-447 (2007).
48. Yoon SK. Recent advances in tumor markers of human hepatocellular carcinoma. Intervirology 51(Suppl. 1), 34-41 (2008).
49. Chignard N, Beretta L. Proteomics for hepatocellular carcinoma marker discovery. Gastroenterology 127(5 Suppl. 1), S120-S125 (2004).
50. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 35(3), 421-430 (2001).
51. Gupta S, Bent S, Kohlwes J. Test characteristics of α-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann. Intern. Med. 139(1), 46-50 (2003).
52. Sterling RK, Jeffers L, Gordon F et al. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am. J. Gastroenterol. 102(10), 2196-2205 (2007).
53. Leerapun A, Suravarapu SV, Bida JP et al. The utility of Lens culinaris agglutinin-reactive α-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin. Gastroenterol. Hepatol. 5(3), 394-402 (2007).
54. Liebman HA, Furie BC, Tong MJ et al. Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N. Engl. J. Med. 310(22), 1427-1431 (1984).
55. Marrero JA, Su GL, Wei W et al. Des-γ carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 37(5), 1114-1121 (2003).
56. Nakamura S, Nouso K, Sakaguchi K et al. Sensitivity and specificity of des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am. J. Gastroenterol. 101(9), 2038-2043 (2006).
57. Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark. 3(2), 79-87 (2007).
58. Capurro M, Wanless IR, Sherman M et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125(1), 89-97 (2003).
59. 2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res. 64(7), 2418-2423 (2004).
60. Iftikhar R, Kladney RD, Havlioglu N et al. Disease- and cell-specific expression of GP73 in human liver disease. Am. J. Gastroenterol. 99(6), 1087-1095 (2004).
61. Marrero JA, Romano PR, Nikolaeva O et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J. Hepatol. 43(6), 1007-1012 (2005).
62. Block TM, Marrero J, Gish RG et al. The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: notes from a recent workshop. Cancer Biomark. 4(1), 19-33 (2008).
63. Wright LM, Kreikemeier JT, Fimmel CJ. A concise review of serum markers for hepatocellular cancer. Cancer Detect. Prev. 31(1), 35-44 (2007).
64. Yamagamim H, Moriyama M, Matsumura H et al. Serum concentrations of human hepatocyte growth factor is a useful indicator for predicting the occurrence of hepatocellular carcinomas in C-viral chronic liver diseases. Cancer 95(4), 824-834 (2002).
65. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J. Natl Cancer Inst. 92(18), 1472-1489 (2000).
66. Tsai JF, Jeng JE, Chuang LY et al. Serum insulin-like growth factor-II and α-fetoprotein as tumor markers of hepatocellular carcinoma. Tumour Biol. 24(6), 291-298 (2003).
67. Tsai JF, Jeng JE, Chuang LY et al. Serum insulin-like growth factor II as a serologic marker of small hepatocellular carcinoma. Scand. J. Gastroenterol. 40(1), 68-75 (2005).
68. Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br. J. Surg. 91(10), 1354-1360 (2004).
69. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGF-β activation. J. Cell Sci. 116(Pt 2), 217-224 (2003).
70. Song BC, Chung YH, Kim JA et al. Transforming growth factor-β1 as a useful serologic marker of small hepatocellular carcinoma. Cancer 94(1), 175-180 (2002).
71. Sacco R, Leuci D, Tortorella C et al. Transforming growth factor β1 and soluble Fas serum levels in hepatocellular carcinoma. Cytokine 12(6), 811-814 (2000).
72. Chau GY, Wu CW, Lui WY et al. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resemble hepatocellular carcinoma. Ann. Surg. 231(4), 552-558 (2000).
73. Hsia CY, Huo TI, Chiang SY et al. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Eur. J. Surg. Oncol. 33(2), 208-212 (2007).
74. Cui R, He J, Zhang F et al. Diagnostic value of protein induced by Vitamin K absence (PIVKAII) and hepatoma-specific band of serum γ-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to α-fetoprotein. Br. J. Cancer 88(12), 1878-1882 (2003).
75. Yoon SBC, Lim NK, Ha SA et al. The human cervical cancer oncogene protein is a biomarker for human hepatocellular carcinoma. Cancer Res. 64(15), 5434-5441 (2004).
76. Masutomi K, Kaneko S, Yasukawa M, Arai K, Murakami S, Kobayashi K. Identification of serum anti-human telomerase reverse transcriptase (hTERT) auto-antibodies during progression to hepatocellular carcinoma. Oncogene 21(38), 5946-5950 (2002).
77. Hann HW, Lee J, Bussard A et al. Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma. Cancer Res. 64(20), 7329-7335 (2004).
78. Zhang J Y, Megliorino R, Peng XX, Tan EM, Chen Y, Chan EK. Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J. Hepatol. 46(1), 107-114 (2007).
79. Poon TC, Yip TT, Chan AT et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin. Chem. 49(5), 752-760 (2003).
80. Paradis V, Degos F, Dargere D et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 41(1), 40-47 (2005).
81. Kanmura S, Uto H, Kusumoto K et al. Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system. Hepatology 45(4), 948-956 (2007).
82. Cui J, Kang X, Dai Z et al. Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification. J. Cancer Res. Clin. Oncol. 133(11), 825-834 (2007).
83. Ward DG, Cheng Y, N'Kontchou G et al. Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis. Br. J. Cancer 94(2), 287-292 (2006).
84. Schwegler EE, Cazares L, Steel LF et al. SELDI-TOF MS profiling of serum for detection of ths progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 41(3), 634-642 (2005).
85. Zinkin NT, Grail F, Bhaskar K et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin. Cancer Res. 14(2), 470-477 (2008).
86. Wu W, Yao DF, Qiu LW et al. Abnormal expression of hepatomas and circulating telomerase and its clinical values. Hepatobiliary Pancreat. Dis. Int. 4(4), 544-549 (2005).
87. Di TL, Franchi G, Park YN et al. Diagnostic value of HSP70, glypican 3 and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 45(3), 725-734 (2007).
88. Okumoto K, Hattori E, Tamura K et al. Possible contribution of circulating transforming growth factor-β1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver Int. 24(1), 21-28 (2004).
89. Kim YJ, Lee HS, Im JP et al. Association of transforming growth factor-β1 gene polymorphisms with a hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. Exp. Mol. Med. 35(3), 196-202 (2003).
90. Joo M, Chi JG, Lee H. Expressions of HSP70 and HSP27 in hepatocellular carcinoma. J. Korean Med. Sci. 20(5), 829-834 (2005).
91. Zeindl-Eberhart E, Haraida S, Liebmann S et al. Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas. Hepatology 39(2), 540-549 (2004).
92. Li C, Tan YX, Zhou H et al. Proteomic analysis of hepatitis B virus-associated hepatocellular carcinoma: identification of potential tumor markers. Proteomics 5(4), 1125-1139 (2005).
93. Llovet JM, Chen Y, Wurmbach E et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 131(6), 1758-1767 (2006).
94. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 10(2 Suppl. 1), S115-S120 (2004).
95. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30(6), 1434-1440 (1999).
96. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 362(9399), 1907-1917 (2003).
97. Llovet JM, Di Bisceglie AM, Bruix J et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst. 100(10), 698-711 (2008).
98. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 47(1), 207-214 (1981).
99. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92(3), 205-216 (2000).
100. Sala M, Llovet JM, Vilana R et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 40(6), 1352-1360 (2004).
101. Clark TW. Chemical ablation of liver cancer. Tech. Vasc. Interv. Radiol. 10(1), 58-63 (2007).
102. Castells A, Bruix J, Bru C et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 18(5), 1121-1126 (1993).
103. Daniele B, de Sio I, Izzo F et al. Hepatic resection and percutaneous ethanol injection as treatments of small hepatocellular carcinoma: a Cancer of the Liver Italian Program (CLIP 08) retrospective case - control study. J. Clin. Gastroenterol. 36(1), 63-67 (2003).
104. Yamamoto J, Okada S, Shimada K et al. Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology 34(4 Pt 1), 707-713 (2001).
105. Huang GT, Lee PH, Tsang YM et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann. Surg. 242(1), 36-42 (2005).
106. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials. Aliment Pharmacol. Ther. 23(11), 1535-1547 (2006).
107. Ryu M, Shimamura Y, Kinoshita T et al. Therapeutic results of resection, transcatheter arterial embolization and percutaneous transhepatic ethanol injection in 3225 patients with hepatocellular carcinoma: a retrospective multicenter study. Jpn. J. Clin. Oncol. 27(4), 251-257 (1997).
108. Gournay J, Tchuenbou J, Richou C et al. Percutaneous ethanol injection vs. resection in patients with small single hepatocellular carcinoma: a retrospective case-control study with cost analysis. Aliment Pharmacol. Ther. 16(8), 1529-1538 (2002).
109. Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology 27(1), 67-72 (1998).
110. Tsai WL, Cheng JS, Lai KH et al. Review article: percutaneous acetic acid injection versus percutaneous ethanol injection for small hepatocellular carcinoma-a long-term follow-up study. Aliment Pharmacol. Ther. DOI: 10.HH/j.1365-2036.2008.03702.x (2008).
111. Huo TI, Huang YH, Wu JC, Lee PC, Chang FY, Lee SD. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study. Scand. J. Gastroenterol. 38(7), 770-778 (2003).
112. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 54(8), 1151-1156 (2005).
113. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 226(2), 441-451 (2003).
114. Huo TI, Lee SD, Wu JC. Ethanol injection versus radiofrequency ablation for hepatocellular carcinoma: which is better? Gastroenterology 128(3), 806-807 (2005).
115. Shiina S, Teratani T, Obi S et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129(1), 122-130 (2005).
116. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 127(6), 1714-1723 (2004).
117. Lencioni RA, Allgaier HP, Cioni D et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 228(1), 235-240 (2003).
118. Chen MS, Zhang YJ, Li JQ, Liang HH, Zhang YQ, Zheng Y. [Randomized clinical trial of percutaneous radiofrequency ablation plus absolute ethanol injection compared with radiofrequency ablation alone for small hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi 27(10), 623-625 (2005).
119. Lu MD, Kuang M, Liang LJ et al. [Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial]. Zhonghua Yi Xue Za Zhi 86(12), 801-805 (2006).
120. Livraghi T, Meloni F, Di SM et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 47(1), 82-89 (2008).
121. Martin RC, Scoggins CR, McMasters KM. Microwave hepatic ablation: initial experience of safety and efficacy. J. Surg. Oncol. 96(6), 481-486 (2007).
122. Lu MD, Xu HX, Xie XY et al. Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study. J. Gastroenterol. 40(11), 1054-1060 (2005).
123. Shibata T, Iimuro Y, Yamamoto Y et al. Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology 223(2), 331-337 (2002).
124. Seki T, Wakabayashi M, Nakagawa T et al. Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma: comparison with percutaneous ethanol injection therapy. Cancer 85(8), 1694-1702 (1999).
125. Zhou XD, Tang ZY. Cryotherapy for primary liver cancer. Semin. Surg. Oncol. 14(2), 171-174 (1998).
126. Callstrom MR, Charboneau JW. Technologies for ablation of hepatocellular carcinoma. Gastroenterology 134(7), 1831-1835 (2008).
127. Pacella CM, Bizzarri G, Francica G et al. Percutaneous laser ablation in the treatment of hepatocellular carcinoma with small tumors: analysis of factors affecting the achievement of tumor necrosis. J. Vasc. Interv. Radiol. 16(11), 1447-1457 (2005).
128. Arienti V, Pretolani S, Pacella CM et al. Complications of laser ablation for hepatocellular carcinoma: a multicenter study. Radiology 246(3), 947-955 (2008).
129. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319), 1734-1739 (2002).
130. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5), 1164-1171 (2002).
131. Camma C, Schepis F, Orlando A et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224(1), 47-54 (2002).
132. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37(2), 429-442 (2003).
133. Marelli L, Stigliano R, Triantos C et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc. Intervent. Radiol. 30(1), 6-25 (2007).
134. Kalayci C, Johnson PJ, Raby N, Metivier EM, Williams R. Intra-arterial adriamycin and lipiodol for inoperable hepatocellular carcinoma: a comparison with intravenous adriamycin. J. Hepatol. 11(3), 349-353 (1990).
135. Chok KS, Ng KK, Poon RT et al. Comparable survival in patients with unresectable hepatocellular carcinoma treated by radiofrequency ablation or transarterial chemoembolization. Arch. Surg. 141(12), 1231-1236 (2006).
136. Doffoel M, Bonnetain F, Bouche O et al. Multicentre randomised Phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolisation for unresectable hepatocellular carcinoma in 9402 cirrhotic patients (Federation Francophone de Cancerologie Digestive). Eur. J. Cancer 44(4), 528-538 (2008).
137. Dharancy S, Boitard J, Decaens T et al. Comparison of two techniques of transarterial chemoembolization before liver transplantation for hepatocellular carcinoma: a case-control study. Liver Transpl. 13(5), 665-671 (2007).
138. Lewis AL, Gonzalez MV, Lloyd AW et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J. Vasc. Interv. Radiol. 17(2 Pt 1), 335-342 (2006).
139. Varela M, Real MI, Burrel M et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J. Hepatol. 46(3), 474-481 (2007).
140. Poon RT, Tso WK, Pang RW et al. A Phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin. Gastroenterol. Hepatol. 5(9), 1100-1108 (2007).
141. Malagari K, Chatzimichael K, Alexopoulou E et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc. Intervent. Radiol. 31(2), 269-280 (2008).
142. Burroughs A, Hochhauser D, Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol. 5(7), 409-418 (2004).
143. Kurokohchi K, Watanabe S, Masaki T et al. Combined use of percutaneous ethanol injection and radiofrequency ablation for the effective treatment of hepatocelluar carcinoma. Int. J. Oncol. 21(4), 841-846 (2002).
144. Kurokohchi K, Watanabe S, Masaki T et al. Combination therapy of percutaneous ethanol injection and radiofrequency ablation against hepatocellular carcinomas difficult to treat. Int. J. Oncol. 21(3), 611-615 (2002).
145. Zhang YJ, Liang HH, Chen MS et al. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. Radiology 244(2), 599-607 (2007).
146. Wong SN, Lin CJ, Lin CC, Chen WT, Cua IH, Lin SM. Combined percutaneous radiofrequency ablation and ethanol injection for hepatocellular carcinoma in high-risk locations. AJR Am. J. Roentgenol. 190(3), W187-W195 (2008).
147. Cheng BQ, Jia CQ, Liu CT et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA 299(14), 1669-1677 (2008).
148. Koda M, Ueki M, Maeda Y et al. The influence on liver parenchymal function and complications of radiofrequency ablation or the combination with transcatheter arterial embolization for hepatocellular carcinoma. Hepatol. Res. 29(1), 18-23 (2004).
149. Wang YB, Chen MH, Yan K, Yang W, Dai Y, Yin SS. Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone. Qual. Life Res. 16(3), 389-397 (2007).
150. Becker G, Soezgen T, Olschewski M, Laubenberger J, Blum HE, Allgaier HP. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J. Gastroenterol. 11(39), 6104-6109 (2005).
151. Dettmer A, Kirchhoff TD, Gebel M et al. Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma. World J. Gastroenterol. 12(23), 3707-3715 (2006).
152. Akamatsu M, Yoshida H, Obi S et al. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial. Liver Int. 24(6), 625-629 (2004).
153. Bartolozzi C, Lencioni R, Caramella D et al. Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology 197(3), 812-818 (1995).
154. Koda M, Murawaki Y, Mitsuda A et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study. Cancer 92(6), 1516-1524 (2001).
155. Zhang FJ, Wu PH, Zhao M, Gu YK, Zhang L, Tan ZB. [Evaluation of combined percutaneous radio-frequency ablation and percutaneous ethanol injection after transcatheter arterial chemoembolization for hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi 27(4), 248-250 (2005).
156. Marelli L, Stigliano R, Triantos C et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat. Rev. 32(8), 594-606 (2006).
157. von Marschall Z, Cramer T, Hocker M, Finkenzeller G, Wiedenmann B, Rosewicz S. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut 48(1), 87-96 (2001).
158. Ueda H, Tanaka H, Kida Y, Fukuchi H, Ichinose M. Adjuvant chemotherapy with tegafur/uracil administration after transcatheter arterial chemoembolization for advanced hepatocellular carcinoma. Oncol. Rep. 19(5), 1355-1361 (2008).
159. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378-390 (2008).
160. Kim JK, Han KH, Lee JT et al. Long-term clinical outcome of Phase IIb clinical trial of percutaneous injection with holmium-166/chitosan complex (Milican) for the treatment of small hepatocellular carcinoma. Clin. Cancer Res. 12(2), 543-548 (2006).
161. Wang XM, Yin ZY, Yu RX, Peng YY, Liu PG, Wu GY. Preventive effect of regional radiotherapy with phosphorus-32 glass microspheres in hepatocellular carcinoma recurrence after hepatectomy. World J. Gastroenterol. 14(4), 518-523 (2008).
162. Leung WT, Lau WY, Ho S et al. Selective internal radiation therapy with intra-arterial iodine-131-lipiodol in inoperable hepatocellular carcinoma. J. Nucl. Med. 35(8), 1313-1318 (1994).
163. 131I-labelled-iodized oil for palliative treatment of hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 17(9), 905-910 (2005).
164. Kanhere HA, Leopardi LN, Fischer L, Kitchener MI, Maddern GJ. Treatment of unresectable hepatocellular carcinoma with radiolabelled lipiodol. ANZ J. Surg. 78(5), 371-376 (2008).
165. Raoul JL, Guyader D, Bretagne JF et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J. Nucl. Med. 35(11), 1782-1787 (1994).
166. 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 26(5), 1156-1161 (1997).
167. Lau WY, Lai EC, Leung TW, Yu SC. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann. Surg. 247(1), 43-48 (2008).
168. 131I-lipiodol in treatment of hepatocellular carcinoma: results of Phase II trial. Int. J. Radial. Oncol. Biol. Phys. 64(3), 745-750 (2006).
169. Padhy AK, Dondi M. A report on the implementation aspects of the International Atomic Energy Agency's first doctoral coordinated research project, "Management of liver cancer using radionuclide methods with special emphasis on trans-arterial radio-conjugate therapy and internal dosimetry". Semin. Nucl. Med. 38(2), S5-S12 (2008).
170. 188Re-HDD as a new therapeutic agent for transhepatic arterial embolization in liver cancer: preclinical study in a rabbit liver cancer model. J. Nucl. Med. 44(12), 2033-2038 (2003).
171. 188Re HDD-labeled iodized oil for treatment - prospective multicenter clinical trial. Radiology 243(2), 509-519 (2007).
172. Bernal P, Raoul JL, Stare J et al. International Atomic Energy Agency-sponsored multination study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study. Semin. Nucl. Med. 38(2), S40-S45 (2008).
173. 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 66(3), 792-800 (2006).
174. Gulec SA, Mesoloras G, Dezarn WA, McNeillie P, Kennedy AS. Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio. J. Transl. Med. 5, 15 (2007).
175. Salem R, Lewandowski RJ, Atassi B et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere), safety, tumor response and survival. J. Vasc. Intern Radiol. 16(12), 1627-1639 (2005).
176. Geschwind JF, Salem R, Carr BI et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127(5 Suppl. 1), S194-S205 (2004).
177. Carr BI. Hepatic arterial 90Yttrium glass microspheres (TheraSphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl. 10(2 Suppl. 1), S107-S110 (2004).
178. Keppke AL, Salem R, Reddy D et al. Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. AJR Am. J. Roentgenol. 188(3), 768-775 (2007).
179. Young JY, Rhee TK, Atassi B et al. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J. Vasc. Intern. Radiol. 18(11), 1375-1382 (2007).
180. 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J. Vasc. Interv. Radiol. 18(1 Pt 1), 49-56 (2007).
181. Kulik LM, Atassi B, van HL et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J. Surg. Oncol. 94(7), 572-586 (2006).
182. Liepe K, Brogsitter C, Leonhard J et al. Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization. Jpn. J. Clin. Oncol. 37(12), 942-950 (2007).
183. Kim TH, Kim DY, Park JW et al. Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am. J. Clin. Oncol. 29(6), 568-575 (2006).
184. Kawashima M, Furuse J, Nishio T et al. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J. Clin. Oncol. 23(9), 1839-1846 (2005).
185. Li YY, Sha WH, Zhou YJ, Nie YQ. Short and long term efficacy of high intensity focused ultrasound therapy for advanced hepatocellular carcinoma. J. Gastroenterol. Hepatol. 22(12), 2148-2154 (2007).
186. Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J. Gastroenterol. 12(47), 7561-7567 (2006).
187. Llovet JM, Bustamante J, Castells A et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 29(1), 62-67 (1999).
188. Pawarode A, Voravud N, Sriuranpong V, Kullavanijaya P, Patt YZ. Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. Am. J. Clin. Oncol. 21(4), 386-391 (1998).
189. Sotiropoulos GC, Radtke A, Schmitz KJ et al. Liver transplantation in the setting of hepatocellular carcinoma and portal vein thrombosis: a challenging dilemma? Dig. Dis. Sci. 53(7), 1994-1999 (2008).
190. Pentecost MJ, Daniels JR, Teitelbaum GP, Stanley P. Hepatic chemoembolization: safety with portal vein thrombosis. J. Vasc. Interv. Radiol. 4(3), 347-351 (1993).
191. Ramsey DE, Geschwind JF. Chemoembolization of hepatocellular carcinoma - what to tell the skeptics: review and meta-analysis. Tech. Vasc. Interv. Radiol. 5(3), 122-126 (2002).
192. Georgiades CS, Hong K, D'Angelo M, Geschwind JF. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J. Vasc. Interv. Radiol. 16(12), 1653-1659 (2005).
193. Fan J, Zhou J, Wu ZQ et al. Efficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumor thrombosis. World J. Gastroenterol. 11(8), 1215-1219 (2005).
194. Li Q, Wang J, Sun Y et al. Efficacy of postoperative transarterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma complicated by portal vein tumor thrombosis - a randomized study. World J. Surg. 30(11), 2004-2011 (2006).
195. Jang JW, Bae SH, Choi JY et al. A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management. Cancer Chemother. Pharmacol. 59(1), 9-15 (2007).
196. Ando E, Tanaka M, Yamashita F et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 95(3), 588-595 (2002).
197. Lai YC, Shih CY, Jeng CM, Yang SS, Hu JT, Sung YC et al. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. World J. Gastroenterol. 9(12), 2666-2670 (2003).
198. Obi S, Yoshida H, Toune R et al. Combination therapy of intra-arterial 5-fluorouracil and systemic interferon-α for advanced hepatocellular carcinoma with portal venous invasion. Cancer 106(9), 1990-1997 (2006).
199. Nagano H, Miyamoto A, Wada H et al. Interferon-α and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. Cancer 110(11), 2493-2501 (2007).
200. Salem R, Lewandowski R, Roberts C et al. Use of yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J. Vasc. Interv. Radiol. 15(4), 335-345 (2004).
201. 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47(1), 71-81 (2008).
202. Takizawa D, Kakizaki S, Sohara N et al. Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis. Dig. Dis. Sci. 52(11), 3290-3295 (2007).